{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:14:30Z","timestamp":1789913670824,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"publisher","award":["CBB-APQ-00819-12"],"award-info":[{"award-number":["CBB-APQ-00819-12"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"publisher","award":["CBB-APQ-01778-2014"],"award-info":[{"award-number":["CBB-APQ-01778-2014"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["APQ-482976\/2012-8"],"award-info":[{"award-number":["APQ-482976\/2012-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["APQ-488237\/2013-0"],"award-info":[{"award-number":["APQ-488237\/2013-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["APQ-467640\/2014-9"],"award-info":[{"award-number":["APQ-467640\/2014-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.trsl.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T02:24:18Z","timestamp":1526955858000},"page":"18-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis"],"prefix":"10.1016","volume":"200","author":[{"given":"Daniel S.","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia A.F.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edvian T.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela P.","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourena E.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Ch\u00e1vez-Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda F.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds T.O.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Ludolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil S.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.O.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexsandro S.","family":"Galdino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana C.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M.","family":"Roatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Menezes-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio L.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo A.F.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.05.001_bib0001","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.05.001_bib0002","first-page":"22","article-title":"Control of the leishmaniases","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.trsl.2018.05.001_bib0003","first-page":"98","article-title":"Recent developments and future prospects in the treatment of visceral leishmaniasis","volume":"3","author":"Sundar","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.trsl.2018.05.001_bib0004","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3389\/fimmu.2017.01779","article-title":"Alternative to chemotherapy-the unmet demand against leishmaniasis","volume":"8","author":"Didwania","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.actatropica.2018.02.010","article-title":"Recent progress in drug targets and inhibitors towards combating leishmaniasis","volume":"181","author":"Vijayakumar","year":"2018","journal-title":"Acta Trop"},{"key":"10.1016\/j.trsl.2018.05.001_bib0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molimm.2016.06.014","article-title":"A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection","volume":"76","author":"Duarte","year":"2016","journal-title":"Molecul Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005951","article-title":"Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis","volume":"11","author":"Cec\u00edlio","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.trsl.2018.05.001_bib0008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13071-016-1553-y","article-title":"Possibilities and challenges for developing a successful vaccine for leishmaniasis","volume":"9","author":"Srivastava","year":"2016","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.trsl.2018.05.001_bib0009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2017.00217","article-title":"Vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden","volume":"8","author":"Roatt","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/pim.12287","article-title":"Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis","volume":"37","author":"Lage","year":"2015","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0011","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.molimm.2016.12.022","article-title":"Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb\/c mice","volume":"82","author":"Amit","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/sji.12557","article-title":"A non-pathogenic recombinant Leishmania expressing lipophosphoglycan 3 against experimental infection with Leishmania infantum","volume":"86","author":"Pirdel","year":"2017","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0013","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.trstmh.2012.07.005","article-title":"Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis","volume":"106","author":"Mukhopadhyay","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.trsl.2018.05.001_bib0014","doi-asserted-by":"crossref","first-page":"e1874","DOI":"10.1371\/journal.pntd.0001874","article-title":"Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis","volume":"6","author":"Singh","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.trsl.2018.05.001_bib0015","first-page":"1","article-title":"Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypotheticalprotein against visceral leishmaniasis","author":"Dias","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.trsl.2018.05.001_bib0016","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.molimm.2017.09.017","article-title":"Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: potential vaccine and diagnostic application against visceral leishmaniasis","volume":"91","author":"Dias","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellimm.2017.11.001","article-title":"Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis","volume":"323","author":"Dias","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0018","doi-asserted-by":"crossref","first-page":"e12359","DOI":"10.1111\/pim.12359","article-title":"A recombinant chimeric protein composed of human and mice-specific CD4+ and CD8+ T-cell epitopes protects against visceral leishmaniasis","volume":"39","author":"Martins","year":"2017","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2249.2005.02768.x","article-title":"Dichotomy of protective cellular immune responses to human visceral leishmaniasis","volume":"140","author":"Khalil","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.trsl.2018.05.001_bib0021","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.4161\/hv.21881","article-title":"Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines","volume":"8","author":"Elfaki","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.trsl.2018.05.001_bib0022","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fmicb.2016.00467","article-title":"Post-genomics and vaccine improvement for Leishmania","volume":"7","author":"Seyed","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0023","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3389\/fimmu.2017.01763","article-title":"Identification of potential MHC Class-II-restricted epitopes derived from Leishmania donovani antigens by reverse vaccinology and evaluation of their CD4+ T-cell responsiveness against visceral leishmaniasis","volume":"8","author":"Dikhit","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0024","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00251-010-0441-4","article-title":"NetCTLpan: pan-specific MHC class I pathway epitope predictions","volume":"62","author":"Stranzl","year":"2010","journal-title":"Immunogenetics"},{"key":"10.1016\/j.trsl.2018.05.001_bib0025","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.0709717105","article-title":"Conditional MHC class I ligands and pep de exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7","volume":"105","author":"Bakker","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.05.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/imm.12889","article-title":"Improved methods for predicting peptide binding affinity to MHC class II molecules","author":"Jensen","year":"2018","journal-title":"Immunology"},{"issue":"W1","key":"10.1016\/j.trsl.2018.05.001_bib0027","doi-asserted-by":"crossref","first-page":"W24","DOI":"10.1093\/nar\/gkx346","article-title":"BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes","volume":"45","author":"Jespersen","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.trsl.2018.05.001_bib0028","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/nar\/gkg563","article-title":"ExPASy: the proteomics server for in-depth protein knowledge and analysis","volume":"31","author":"Gasteiger","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.trsl.2018.05.001_bib0029","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.imbio.2017.10.043","article-title":"Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasis","volume":"223","author":"Portela","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.trsl.2018.05.001_bib0030","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Coelho","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.trsl.2018.05.001_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0003-2697(82)90118-X","article-title":"Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids","volume":"126","author":"Green","year":"1982","journal-title":"Anal Biochem"},{"key":"10.1016\/j.trsl.2018.05.001_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mib.2012.05.002","article-title":"Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives","volume":"15","author":"Fernandes","year":"2012","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0033","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","article-title":"Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis","volume":"150","author":"Rachamim","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0034","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1645\/0022-3395(2000)086[0730:IOPPAL]2.0.CO;2","article-title":"Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes","volume":"86","author":"Afrin","year":"2000","journal-title":"J Parasitol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.micinf.2008.06.002","article-title":"Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice","volume":"10","author":"Iborra","year":"2008","journal-title":"Microbes Infect"},{"key":"10.1016\/j.trsl.2018.05.001_bib0036","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2012.05.075","article-title":"Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis","volume":"30","author":"Agallou","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.05.001_bib0037","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2016.07.017","article-title":"Direct evidence for role of anti-saliva antibodies against salivary gland homogenate of P. argentipes in modulation of protective Th1-immune response against Leishmania donovani","volume":"86","author":"Pushpanjali","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.trsl.2018.05.001_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fimmu.2017.00227","article-title":"Leishmania donovani nucleoside hydrolase (NH36) domains induce T-cell cytokine responses in human visceral leishmaniasis","volume":"8","author":"Barbosa-Santos","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0039","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s13071-017-2576-8","article-title":"Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection","volume":"10","author":"Ramos","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.trsl.2018.05.001_bib0040","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.trsl.2018.05.001_bib0041","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/CVI.05024-11","article-title":"KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis","volume":"18","author":"Goto","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fimmu.2016.00327","article-title":"Combination of in silico methods in the search for potential CD4(+) and CD8(+) T cell epitopes in the proteome of Leishmania braziliensis","volume":"7","author":"Silva","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0043","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fimmu.2014.00268","article-title":"Experimental validation of multi-epitope peptides including promising mhc class I- and II-restricted epitopes of four known Leishmania infantum Proteins","volume":"5","author":"Agallou","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0044","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmc.2017.07.013","article-title":"In silico analysis and in vitro evaluation of immunogenic and immunomodulatory properties of promiscuous peptides derived from Leishmania infantum eukaryotic initiation factor","volume":"25","author":"Koutsoni","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.trsl.2018.05.001_bib0045","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","article-title":"Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells","volume":"26","author":"Resende","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.05.001_bib0046","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fimmu.2017.00100","article-title":"A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani nucleoside hydrolase (NH36) optimizes cross-protection against Leishmania amazonesis infection","volume":"8","author":"Alves-Silva","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0047","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/ijms18020371","article-title":"Immunoinformatics features linked to Leishmania vaccine development: data integration of experimental and in silico studies","volume":"18","author":"Brito","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2018.05.001_bib0048","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.05.001_bib0049","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-3024.2006.00817.x","article-title":"Immunohistological features of visceral leishmaniasis in BALB\/c mice","volume":"28","author":"Carri\u00f3n","year":"2006","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0050","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00436-011-2628-5","article-title":"Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB\/c mice using different doses and routes of inoculation of parasites","volume":"110","author":"Oliveira","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.trsl.2018.05.001_bib0051","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s13071-016-1752-6","article-title":"Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec\u00ae and Leishmune\u00ae vaccines against visceral leishmaniasis","volume":"9","author":"Mendon\u00e7a","year":"2016","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.trsl.2018.05.001_bib0052","doi-asserted-by":"crossref","first-page":"e2174","DOI":"10.1371\/journal.pntd.0002174","article-title":"Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis","volume":"7","author":"Saljoughian","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.trsl.2018.05.001_bib0053","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-3305-7-3","article-title":"Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis","volume":"7","author":"Ramirez","year":"2014","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.trsl.2018.05.001_bib0054","doi-asserted-by":"crossref","first-page":"e12345","DOI":"10.1111\/pim.12345","article-title":"Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB\/c mice","volume":"39","author":"Pirdel","year":"2017","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.trsl.2018.05.001_bib0055","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.vaccine.2016.04.067","article-title":"Strategic evaluation of vaccine candidate antigens for the prevention of visceral leishmaniasis","volume":"34","author":"Duthie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.05.001_bib0056","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fcimb.2017.00200","article-title":"IFN-\u03b3, IL-2, IP-10, and MIG as biomarkers of exposure to Leishmania spp., and of cure in human visceral leishmaniasis","volume":"7","author":"Ibarra-Meneses","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"Suppl 2","key":"10.1016\/j.trsl.2018.05.001_bib0057","first-page":"B244\u00b19","article-title":"Case study for a vaccine against leishmaniasis","volume":"31","author":"Alvar","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.05.001_bib0058","doi-asserted-by":"crossref","first-page":"1462\u00b170","DOI":"10.1111\/j.1469-0691.2011.03610.x","article-title":"Visceral leishmaniasis: immunology and prospects for a vaccine","volume":"17","author":"Kaye","year":"2011","journal-title":"Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.trsl.2018.05.001_bib0059","doi-asserted-by":"crossref","first-page":"417\u00b125","DOI":"10.4269\/ajtmh.2012.10-0415","article-title":"The economic value of a visceral leishmaniasis vaccine in Bihar state, India","volume":"86","author":"Lee","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.trsl.2018.05.001_bib0060","doi-asserted-by":"crossref","first-page":"423\u00b1424","DOI":"10.1093\/trstmh\/trv039","article-title":"Development of Leishmania vaccines in the era of visceral leishmaniasis elimination","volume":"109","author":"Engwerda","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:03:17Z","timestamp":1693681397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418300847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":60,"alternative-id":["S1931524418300847"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.05.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}